A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response.

A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response.

Publication date: Mar 29, 2024

COVID-19 caused by SARS-CoV-2 spread rapidly around the world, endangering the health of people globally. The SARS-CoV-2 spike protein initiates entry into target cells by binding to human angiotensin-converting enzyme 2 (ACE2). In this study, we developed DNA aptamers that specifically bind to the SARS-CoV-2 spike protein, thereby inhibiting its binding to ACE2. DNA aptamers are small nucleic acid fragments with random structures that selectively bind to various target molecules. We identified nine aptamers targeting the SARS-CoV-2 spike protein using the systematic evolution of ligands by exponential enrichment (SELEX) method and selected three optimal aptamers by comparing their binding affinities. Additionally, we confirmed that the DNA aptamers suppressed pro-inflammatory cytokines induced by the SARS-CoV-2 spike protein in ACE2-overexpressing HEK293 cells. Overall, the DNA aptamer developed in this study has the potential to bind to the SARS-CoV-2 spike protein and inhibit or block its interaction with ACE2. Thus, our DNA aptamers can be used as new biological tools for the prevention and diagnosis of SARS-CoV-2 infection.

Open Access PDF

Concepts Keywords
Ace2 ACE2
Covid Aptamer
Inflammatory Diagnostic
Proteins Prevention
Target SARS-CoV-2


Type Source Name
disease MESH COVID-19
drug DRUGBANK Angiotensin II
drug DRUGBANK Coenzyme M
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH Viral infections
disease MESH complications
disease MESH inflammation
disease MESH cytokine storm
disease IDO contact tracing
disease IDO history
disease VO time
disease MESH Infectious Diseases
disease VO age
disease VO storage
drug DRUGBANK Lopinavir
drug DRUGBANK Ritonavir
disease MESH infections
disease VO effective
disease VO effectiveness
disease IDO process
drug DRUGBANK 5-amino-1 3 4-thiadiazole-2-thiol
drug DRUGBANK Thiocolchicoside
disease VO Glycoprotein
drug DRUGBANK Imidazole
disease VO volume
disease VO USA
drug DRUGBANK Adenine
disease VO Canada
drug DRUGBANK Ampicillin
disease VO efficiency
disease VO gene
disease IDO algorithm
drug DRUGBANK Streptomycin
disease VO manufacturer
drug DRUGBANK Tretamine
disease VO protocol
drug DRUGBANK Indoleacetic acid
disease VO TTC
drug DRUGBANK Timonacic
disease VO Tat
disease VO Gag
drug DRUGBANK 7-Methyl-Gpppa
drug DRUGBANK Trihexyphenidyl
disease IDO host
disease MESH severe acute respiratory syndrome
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Vorinostat
disease VO vaccine
disease IDO pathogen
disease IDO infection
disease IDO assay
drug DRUGBANK Gold
drug DRUGBANK Trestolone
disease MESH syndromes
disease IDO immunosuppression
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease IDO cell
drug DRUGBANK Lactobacillus plantarum

Original Article

(Visited 1 times, 1 visits today)